Philippe G. Prokocimer
Plus aucun poste en cours
Historique de carrière de Philippe G. Prokocimer
Anciens postes connus de Philippe G. Prokocimer
Sociétés | Poste | Début | Fin |
---|---|---|---|
Johnson & Johnson Pharmaceutical Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Directeur Technique/Scientifique/R&D | 01/01/2007 | 01/01/2007 |
Maxim Pharmaceuticals, Inc. | Directeur Technique/Scientifique/R&D | 01/01/2003 | 01/01/2003 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Directeur Technique/Scientifique/R&D | 01/01/2001 | 01/01/2001 |
ABBOTT LABORATORIES | Directeur Technique/Scientifique/R&D | 01/01/1994 | 01/01/1994 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 11/07/2007 | - |
Formation de Philippe G. Prokocimer
Centre Hospitalier Universitaire Pitie-Salpetriere | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
France | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Entreprise privées | 4 |
---|---|
Maxim Pharmaceuticals, Inc. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Johnson & Johnson Pharmaceutical Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Commercial Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Philippe G. Prokocimer
- Expérience